Liquidia Corporation
LQDA
Rang în acțiuni
#4751
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Preț acțiune
$35.83
Capitalizare de piață
$3.21B
Schimbare (1 zi)
4.98%
Schimbare (1 an)
46.60%
Țară
US
Tranzacționează Liquidia Corporation (LQDA)
Categorie
Healthcare
Raport P/S pentru Liquidia Corporation (LQDA)
Raport P/S la data de October 2026 TTM: 6.74
Conform celor mai recente rapoarte financiare și prețului acțiunilor Liquidia Corporation, raportul P/S actual (TTM) este 6.74. La sfârșitul anului 2023, compania avea un P/S de 44.71.
Istoricul raportului P/S pentru Liquidia Corporation din 2016 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 6.74 | -89.81% |
| 2024 | 66.13 | 47.92% |
| 2023 | 44.71 | 83.47% |
| 2022 | 24.37 | 29.46% |
| 2021 | 18.82 | -86.07% |
| 2020 | 135.16 | 1,280.87% |
| 2019 | 9.79 | -82.92% |
| 2018 | 57.32 | 336.47% |
| 2017 | 13.13 | 82.10% |
| 2016 | 7.21 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.31 | 53.04% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 124.46% |
US
|
